NANJING, China, Oct. 21 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical
Group (NYSE: SCR), a leading manufacturer and supplier of branded generic
pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly
growing China market, announced today that it intends to release its 2008
third quarter results on Thursday, November 6, 2008, before the market
opens in the United States. Simcere's chief executive officer, Jinsheng
Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings
conference call to discuss the company's 2008 third quarter results on
Thursday, November 6, at 8 a.m. ET (Thursday, November 6, at 9 p.m.
Beijing/Hong Kong time).
To access the conference call, please dial:
United States toll-free dial-in number: +1-866-314-4483
United States toll / International dial-in number: +1-617-213-8049
China toll-free dial-in number: 10-800-130-0399
Hong Kong dial-in number: +852-3002-1672
Please ask to be connected to Simcere's Q3 2008 Earnings Call and provide the following passcode: 91351092. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's Web site at http://www.simcere.com .
Following the earnings conference call, an archive of the call will be
available by dialing:
United States toll-free dial-in number: +1-888-286-8010
United States toll / International dial-in number: +1-617-801-6888
The passcode for replay participants is: 53343092. The telephone replay also will be archived on the "Investor Relations" section of the company's Web site at http://www.simcere.com for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti-stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 39 principal pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
|SOURCE Simcere Pharmaceutical Group|
Copyright©2008 PR Newswire.
All rights reserved